

Advance_HTA Capacity Building Workshop

09-10 September 2015

Grand Hyatt Hotel - Santiago, Chile

Day 1 - Wednesday 09 September, 2015

08:30-08:45 Arrival and Registration

08:45-09:00 Welcome and Introduction, **Panos Kanavos (LSE) and Alexandre Lemgruber (PAHO)**

09:00-09:15 Opening Note, **Ministry of Health of Chile**

09:15-11:15 Session 1: Assessing Value for Money

- How Can Value for Money Be Assessed?, **John Cairns (LSHTM)** 09:15-09:30

- Why Do Some Countries Approve a Cancer Drug and Others

Don't?, **John Cairns (LSHTM)**

- Policy Reactions: **Marianela Castillo (MoH, Chile), Ryota** 09:55-10:05

Nakamura (University of York, UK)

Q&A/Debate 10:05-10:20

- Breakout Session: *Assessing the Value of Cancer Drugs* 10:20-11:00

- Group Work Results 11:00-11:15

11:15-11:30 *Coffee Break*

11:30-13:30 Session 2: Value Assessment in Health Technology

- State of the Art: Methods of Value Assessment – Challenges and

Limitations, **Panos Kanavos (LSE)** 11:30-11:45

- Value Assessment: Building Value Propositions from an HTA

Perspective, **Aris Angelis and Panos Kanavos (LSE)** 11:45-12:10

- Policy Reactions: **Andrea Basagoitia (ISP, Chile), Ruth Jimbo (MoH,** 12:10-12:20

Ecuador)

Q&A/Debate 12:20-12:35

- Breakout Session: *Case Studies* 12:35-13:15

- Group Work Results 13:15-13:30

13:30-14:15 Lunch

14:15-16:15 **Session 3: Using Alternative Methods to Assess Value of New Medical Technologies**

- Using Multiple-Criteria Decision Analysis: Conceptual Framework and Model, **Panos Kanavos (LSE)** 14:15-14:35
- MCDA application: Empirical evidence, **Aris Angelis and Panos Kanavos (LSE)** 14:35-14:55
- Policy Reactions: **Aurelio Mejía (IETS, Colombia), Victor Dongo (IETSI, Peru)** 14:55-15:05
- Q&A/Debate 15:05-15:20
- Breakout Session: *Case Study* 15:20-16:00
- Group Work Results 16:00-16:15

16:15-16:30 Coffee Break

16:30-18:30 **Session 4: HTA and Rare Disease: Assessing the Societal Value of Orphan Drugs**

- Particularities of the Orphan Drug Market Access Environment – A Quick Overview, **Elena Nicod (LSE)** 16:30-16:45
- Evidence in Dealing with Orphan Drugs and Policy Recommendations, **Elena Nicod (LSE)** 16:45-17:10
- Policy Reactions: **Alejandra Croci (MoH, Uruguay), Augusto Guerra (UFMG, Brasil)** 17:10-17:20
- Q&A/Debate 17:20-17:35
- Breakout Session: *Orphan Drugs Coverage in Latin America* 17:35-18:15
- Group Work Results 18:15-18:30

18:30 Summary and Close of Day 1

Day 2 – Thursday 10 September, 2015

08:30-09:00 Arrival and Registration

09:00-09:15 Introduction, **Panos Kanavos (LSE) and Alexander Lemgruber (PAHO)**

09:15-11:15 Session 5: HTA and Medical Devices

- Evaluation of Medical Devices: How Is It Different? Current Practices Across European HTA Agencies, **Dimitra Panteli, Sabine Fuchs (TUB)** 09:15-09:30
- Approaching the Evaluation of Different Types of Medical Devices Based on a New Taxonomic Model, **Dimitra Panteli, Sabine Fuchs (TUB)** 09:30-09:55
- Policy Reactions: **Alicia Framarin (INESSS, Canada), Elkin Otalvaro (INVIMA, Colombia)** 09:55-10:05
- Q&A/Debate 10:05-10:20
- Breakout Session 10:20-11:00
- Group Work Results 11:00-11:15

11:15-11:30 *Coffee Break*

11:30-13:30 Session 6: Strengthening and Implementing HTA in Emerging Settings

- The Importance of HTA in Emerging Settings - The REDETSA Experience, **Alexandre Lemgruber (PAHO)** 11:30-11:45
- HTA in Emerging Settings - Mapping Exercise and Toolbox, **Jaime Espin (EASP)** 11:45-12:10
- Policy Reactions: **Vania Canuto (CONITEC, Brasil), Ana Eduvigis Sancho (MoH, Costa Rica)** 12:10-12:20
- Q&A/Debate 12:20-12:35
- Breakout Session: *Challenges in HTA implementation in Latin America* 12:35-13:15
- Group Work Results 13:15-13:30

13:30-14:15 *Lunch*

14:15-14:30 Lessons Learnt, Policy Recommendations and Advances in HTA
Panos Kanavos (LSE)

14:30-15:00 Distribution of Certificates and Close of Workshop, **Panos Kanavos (LSE)**
and **Alexandre Lemgruber (PAHO)**

15:00

Workshop Ends